Etrumadenant
As of the edition of 20 October 2026, Etrumadenant is a small molecule: in active development; acts on ADORA2A and ADORA2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2029
- Kind
- Small molecule
- Registered trials
- 22, 3 stopped early
- Disease areas
- Cancer; Lungs and airways; Urinary and reproductive; Digestive system; Hormones; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Etrumadenant.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 7 | 0 | 1 |
| Phase 2 | 14 | 4 | 8 | 2 |
| All trials | 22 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Roche | Lead sponsor of trials | 2017 to now |
| Arcus Biosciences | Lead sponsor of trials | 2018 to now |
| Coherus Oncology | Lead sponsor of trials | 2022 to now |
| Gilead Sciences | Lead sponsor of trials | 2023 to now |